Chemical activators of ZFP386 engage in diverse cellular mechanisms to modulate its activity. Forskolin, by directly stimulating adenylate cyclase, increases intracellular levels of cAMP, which in turn activates protein kinase A (PKA). PKA is then able to phosphorylate ZFP386, leading to its activation. Similarly, IBMX and Rolipram function by inhibiting phosphodiesterases 4 and 5, respectively, which are responsible for cAMP breakdown. Their inhibitory action results in the accumulation of cAMP within the cell, further activating PKA and subsequently ZFP386. The selective inhibition of PDE5 by Zaprinast also contributes to the elevation of cAMP, thereby fostering a conducive environment for PKA-mediated phosphorylation of ZFP386. In addition, Dibutyryl-cAMP, a synthetic analog of cAMP, directly activates PKA, hence facilitating the activation of ZFP386.
Other chemical activators function through alternative pathways. Okadaic Acid, a protein phosphatase inhibitor, prevents the dephosphorylation of proteins, which may result in the sustained activation of ZFP386. Anisomycin triggers the stress-activated protein kinase pathways, including JNK and p38 MAP kinase, which may target ZFP386 for phosphorylation. Activation of protein kinase C (PKC) by Phorbol 12-myristate 13-acetate (PMA) also leads to the phosphorylation of multiple substrates, including ZFP386. Flavopiridol inhibits cyclin-dependent kinases, possibly affecting the phosphorylation status of transcription-regulating proteins and influencing the activation state of ZFP386. Compounds like Epigallocatechin gallate (EGCG) and Curcumin can activate PKA or PKC, which may phosphorylate and activate ZFP386. Finally, Sodium Orthovanadate acts as a phosphatase inhibitor, which can maintain ZFP386 in an activated state by preventing its dephosphorylation. Together, these chemicals utilize a variety of intracellular signaling pathways and molecular mechanisms to activate ZFP386, each contributing to the phosphorylation status and functional state of the protein.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin activates adenylate cyclase, leading to an increase in intracellular cAMP levels. Elevated cAMP activates protein kinase A (PKA), which can then phosphorylate and activate ZFP386 as part of a signaling cascade. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
IBMX inhibits phosphodiesterases, preventing the breakdown of cAMP. This action results in the accumulation of cAMP within the cell, which activates PKA. PKA can phosphorylate ZFP386, leading to its activation. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $103.00 $245.00 | 8 | |
Zaprinast selectively inhibits phosphodiesterase 5 (PDE5), causing an increase in cAMP levels due to reduced degradation. The elevation of cAMP activates PKA, which may result in the phosphorylation and activation of ZFP386. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $75.00 $212.00 | 18 | |
Rolipram selectively inhibits phosphodiesterase 4 (PDE4), increasing intracellular levels of cAMP and thereby activating PKA. Activated PKA can lead to the phosphorylation and activation of ZFP386. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $285.00 $520.00 $1300.00 | 78 | |
Okadaic Acid inhibits protein phosphatases 1 and 2A, leading to increased phosphorylation levels of cellular proteins. This inhibition can result in the sustained activation of ZFP386 through its phosphorylated state. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $97.00 $254.00 | 36 | |
Anisomycin activates the stress-activated protein kinase pathways, including JNK and p38 MAP kinase. These kinases can phosphorylate transcription factors and may target ZFP386 for phosphorylation and subsequent activation. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA activates protein kinase C (PKC), which is involved in a wide range of signaling pathways. PKC can phosphorylate and activate ZFP386 as part of its downstream effects. | ||||||
Brivanib alaninate | 649735-63-7 | sc-480337 | 10 mg | $720.00 | ||
Flavopiridol inhibits cyclin-dependent kinases, which may change the phosphorylation status of proteins involved in transcription regulation. Through this mechanism, Flavopiridol might lead to the activation of ZFP386 by altering the transcriptional machinery. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $36.00 $68.00 $107.00 $214.00 $234.00 $862.00 $1968.00 | 47 | |
Curcumin can activate various signaling pathways, potentially leading to the activation of PKA or PKC. These kinases can phosphorylate and activate ZFP386. | ||||||
Sodium Orthovanadate | 13721-39-6 | sc-3540 sc-3540B sc-3540A | 5 g 10 g 50 g | $45.00 $56.00 $183.00 | 142 | |
Sodium Orthovanadate acts as a phosphatase inhibitor, potentially keeping proteins like ZFP386 in a phosphorylated and activated state. | ||||||